发明名称 FACTOR XA INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF
摘要 PURPOSE: Provided are a compound with aryl-amidines, particularly amidinoaryl-cyclopropanes, amidinoarylmethyl-pyrroles, amidinoaryl-benzenes, amidinoaryl-pyridines, or amidinoaryl-alanines, represented by formula (1), a pharmaceutically acceptable salt, a prodrug, a hydrate, a solvate or an isomer thereof, which are inhibitors of coagulation enzyme, factor Xa (FXa). Also, provided are a pharmaceutical composition containing the compound, and a method of using the same as an anticoagulant agent for the treatment and the prevention of thrombosis disorders. CONSTITUTION: The novel compound of the formula(1) has a good FXa inhibition activity and consequently an excellent selectivity against trypsin and thrombin. In the formula(1), Ar is selected from the groups consisting of benzene, pyridine, thiophene, naphthalene and isoquinoline; G is selected from the groups consisting of R, F, Cl, Br, I, CN, OR, OCOR, CO2R and CONR2, where R represents H or a linear, branched, cyclic or branched cyclic alkyl group having 1 to 10 of carbon atoms; A is selected from the groups consisting of Al, A2, A3 and A4; D represents-NH2, or-CH2NH2; L is a simple linker and represents -(CH2)m-(m = 0, 1); P is selected from the groups consisting of phenyl, pyridine, pyrrole, furan, thiophene, oxazole, isoxazole, imidazole, 1, 2-diazole, thiazole, isothiazole, pyridazine(1, 2-diazine), pyrimidine, pyrazine(1, 4-diazine), naphthalene, quinoline, isoquinoline, benzofuran, benzothiophene, and indole; X is selected from the groups consisting of R, F, Cl, Br, I, CN, OR, COA COR, CONR2, NR2, NR((C=O) R), CF3, OCF3, SO2NR2, SONR2, SO2R, SOR, N ((C=O) R)2, imidazole, 1, 2-diazole, thiazole, isothiazole, pyridazine(= 1, 2-diazine), pyrimidine, pyrazine(= 1, 4-diazine), 1, 2, 3-triazole, 1, 2, 4-triazole, tetrazole, 1, 3, 5-triazine, (1, 2)-imidazoline-2-yl, N-methyl- (1, 2)-imidazoline-2-yl, and NHC (=NR) R; n represents a number of 0, 1 or 2; Q represents hydrogen or is selected from the groups consisting of phenyl, pyridine,pyrrole, furan, thiophene, oxazole, isoxazole, imidazole, 1, 2-diazole, thiazole, isothiazole, pyridazine(= 1, 2-diazine), pyrimidine, and pyrazine(= 1, 4-diazine), provided that when Q represents hydrogen, the substituents Y and Z are meant to be directly connected to P; and Y and Z are independently selected from the group consisting of R, F, Cl, Br, I, CN, OR, COA COR, CONR2, NR2, NR((C=O) R), N((C=O) R)2, CF3, OCF3, SO2NR2, SONR2, SOA SOR, imidazole, 1, 2-diazole, thiazole, isothiazole, pyridazine (=1, 2-diazine), pyrimidine, pyrazine (= 1, 4-diazine), 1, 2, 3-triazole, 1, 2, 4-triazole, tetrazole and 1, 3, 5-triazine.
申请公布号 KR20020070385(A) 申请公布日期 2002.09.06
申请号 KR20027009662 申请日期 2002.07.26
申请人 LG LIFE SCIENCES LTD. 发明人 HUH, YONG SEOK;HWANG, GWANG YEON;JANG, HYE GYEONG;KANG, MYEONG GYUN;KIM EUNICE EUN KYEONG;KWON, O HWAN;LEE, SANG GU;LEE, SEON HWA;LEE, SEUNG HAK;LEE, TAE HUI;MUN, GWANG YUL;PARK, DU HUI;PARK, HUI DONG;PARK, JONG U;PARK, SU GYEONG;PARK, TAE GYO
分类号 C07D213/04;A61K31/155;A61K31/167;A61K31/17;A61K31/18;A61K31/198;A61K31/216;A61K31/27;A61K31/277;A61K31/381;A61K31/40;A61K31/41;A61K31/417;A61K31/4178;A61K31/4196;A61K31/421;A61K31/426;A61K31/44;A61K31/4418;A61K31/4436;A61K31/4439;A61K31/4725;A61K31/5377;A61P7/02;A61P9/00;C07C257/18;C07C259/18;C07C271/20;C07C271/22;C07C271/64;C07C275/24;C07C275/40;C07C275/42;C07C311/06;C07C311/13;C07C311/16;C07C311/19;C07C311/29;C07C311/44;C07C311/46;C07C311/48;C07C317/40;C07C317/44;C07D207/26;C07D207/27;C07D207/32;C07D207/333;C07D207/34;C07D213/40;C07D213/75;C07D213/78;C07D213/81;C07D213/82;C07D213/84;C07D217/22;C07D233/64;C07D233/84;C07D249/12;C07D263/22;C07D263/38;C07D265/10;C07D275/02;C07D277/20;C07D277/56;C07D333/34;C07D333/38;C07D401/10;C07D401/12;C07D403/10;C07D409/06;C07D409/12;C07D413/06;C07D417/06;C07D521/00;(IPC1-7):C07D213/04 主分类号 C07D213/04
代理机构 代理人
主权项
地址